Analysts at Cantor Fitzgerald started coverage on shares of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) in a report issued on Tuesday, The Fly reports. The brokerage set an “overweight” rating on the biotechnology company’s stock.

ALDX has been the topic of a number of other research reports. Zacks Investment Research raised Aldeyra Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Thursday, August 10th. HC Wainwright set a $18.00 price target on Aldeyra Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. ValuEngine raised Aldeyra Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 12th. Canaccord Genuity reaffirmed a “buy” rating and set a $27.00 price target (up previously from $12.00) on shares of Aldeyra Therapeutics in a research note on Wednesday, September 13th. Finally, Cowen and Company reaffirmed an “outperform” rating and set a $14.00 price target (up previously from $9.00) on shares of Aldeyra Therapeutics in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $15.95.

Shares of Aldeyra Therapeutics (ALDX) traded down 2.36% during midday trading on Tuesday, hitting $6.20. 322,487 shares of the company were exchanged. The firm’s market cap is $38.72 million. The company’s 50 day moving average price is $6.98 and its 200 day moving average price is $5.17. Aldeyra Therapeutics has a one year low of $3.80 and a one year high of $11.90.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. Equities analysts expect that Aldeyra Therapeutics will post ($1.51) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Cantor Fitzgerald Initiates Coverage on Aldeyra Therapeutics, Inc. (ALDX)” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/10/24/cantor-fitzgerald-initiates-coverage-on-aldeyra-therapeutics-inc-aldx.html.

In other news, major shareholder Life Sciences Maste Perceptive purchased 200,000 shares of the business’s stock in a transaction dated Tuesday, September 19th. The shares were acquired at an average price of $7.25 per share, with a total value of $1,450,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 28.40% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ALDX. Virtu KCG Holdings LLC bought a new stake in Aldeyra Therapeutics in the second quarter valued at about $104,000. Renaissance Technologies LLC bought a new stake in Aldeyra Therapeutics in the first quarter valued at about $132,000. Hikari Power Ltd increased its holdings in Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock valued at $507,000 after purchasing an additional 70,196 shares during the last quarter. Vanguard Group Inc. increased its holdings in Aldeyra Therapeutics by 3.2% in the second quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock valued at $1,431,000 after purchasing an additional 9,407 shares during the last quarter. Finally, Sphera Funds Management LTD. increased its holdings in Aldeyra Therapeutics by 31.0% in the second quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares during the last quarter. Institutional investors and hedge funds own 40.32% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

The Fly

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.